Publication date: Jul 07, 2026
Psilocybin is a rapid-acting antidepressant, but its mechanism of action in major depressive disorder remains unclear. In this secondary analysis of randomized, placebo-controlled trial with multimodal CSF and blood biomarker measurements, psilocybin selectively reduced CSF galanin and noradrenaline, implicating that normalization of these co-transmitters is a key pharmacodynamic signature.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Norepinephrine |
| drug | DRUGBANK | Psilocybine |
| disease | MESH | major depressive disorder |
| drug | DRUGBANK | Nandrolone phenpropionate |
| disease | MESH | David |
| disease | MESH | treatment resistant depression |
| drug | DRUGBANK | Sulpiride |
| disease | MESH | included |
| pathway | REACTOME | Metabolism |
| drug | DRUGBANK | Citalopram |
| drug | DRUGBANK | Niacin |
| drug | DRUGBANK | Water |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | SOST |
| drug | DRUGBANK | Epinephrine |
| drug | DRUGBANK | Serotonin |
| pathway | REACTOME | Methylation |
| disease | MESH | anxiety |
| disease | MESH | mental disorders |
| drug | DRUGBANK | Escitalopram |
| disease | MESH | inflammation |
| pathway | REACTOME | Reproduction |
Original Article
(Visited 40 times, 1 visits today)